| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Dual specificity tyrosine-phosphorylation-regulated kinase 2, DYRK2 |
| Entrez GeneID | 8445 |
| WB Predicted band size | 66.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This DYRK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 105-135 amino acids from the N-terminal region of human DYRK2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于DYRK2 (N-term)抗体的3篇参考文献及其简要摘要：
---
1. **文献名称**：*DYRK2 phosphorylates p53 and regulates chemosensitivity in cancer cells*
**作者**：Taira N., Yoshida K.
**摘要**：该研究利用DYRK2 (N-term)抗体进行免疫沉淀和免疫印迹实验，证明DYRK2通过磷酸化p53蛋白增强其在DNA损伤后的稳定性，从而调控肿瘤细胞的化疗敏感性。抗体特异性验证显示其可识别内源性DYRK2的N端表位。
---
2. **文献名称**：*Characterization of DYRK2 kinase activity and substrate specificity*
**作者**：Mercher S. et al.
**摘要**：作者通过DYRK2 (N-term)抗体的免疫荧光实验，定位DYRK2在细胞质中的分布，并验证其在多种癌细胞系中的表达水平。研究进一步揭示了DYRK2对特定底物的磷酸化模式及其在细胞周期调控中的作用。
---
3. **文献名称**：*Development of a monoclonal antibody targeting the N-terminal region of DYRK2 for functional studies*
**作者**：Kawakubo T. et al.
**摘要**：本文报道了一种新型DYRK2 (N-term)单克隆抗体的开发与验证。通过Western blot和免疫组化实验，证明该抗体具有高特异性和敏感性，适用于检测DYRK2在多种组织样本中的表达，并用于研究其在癌症转移中的潜在作用。
---
注：以上文献为示例，实际引用需根据具体研究匹配真实发表的论文。建议通过PubMed或Web of Science以“DYRK2 antibody”及“N-terminal”为关键词检索相关文献。
The DYRK2 (N-term) antibody is designed to target the N-terminal region of dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2), a member of the DYRK family of serine/threonine kinases. DYRK2 plays critical roles in cell cycle regulation, DNA damage response, and apoptosis by phosphorylating substrates such as p53. c-Jun, and HSP72/HSC70. It is implicated in diverse cellular processes, including proteasome regulation, where it phosphorylates and promotes the degradation of substrates like Gli1 in the Hedgehog signaling pathway. Dysregulation of DYRK2 has been linked to cancer progression, neurodegenerative disorders, and metabolic diseases, making it a potential therapeutic target.
The antibody is commonly used in research applications like Western blotting, immunoprecipitation, and immunofluorescence to detect endogenous DYRK2 expression and study its localization, interactions, and post-translational modifications. Its specificity for the N-terminal region ensures recognition of full-length DYRK2 (approximately 100 kDa) while minimizing cross-reactivity with other DYRK family members. Validated in human, mouse, and rat samples, the antibody aids in exploring DYRK2’s role in cellular stress responses, tumor suppression, and its interaction with pathways like mTOR and Wnt. Researchers also utilize it to investigate DYRK2 inhibitors in preclinical models, emphasizing its relevance in both basic and translational studies.
×
